Adamas Pharmaceuticals’ (ADMS) “Buy” Rating Reaffirmed at HC Wainwright

Share on StockTwits

Adamas Pharmaceuticals (NASDAQ:ADMS)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research note issued to investors on Monday, AnalystRatings.com reports. They presently have a $30.00 price objective on the specialty pharmaceutical company’s stock. HC Wainwright’s price objective would suggest a potential upside of 360.83% from the stock’s current price.

A number of other research firms have also recently weighed in on ADMS. Cowen set a $5.00 target price on shares of Adamas Pharmaceuticals and gave the company a “hold” rating in a research note on Friday, August 9th. Evercore ISI reiterated a “buy” rating and issued a $55.00 price target on shares of Adamas Pharmaceuticals in a research note on Monday, August 12th. Cantor Fitzgerald initiated coverage on Adamas Pharmaceuticals in a report on Monday, September 9th. They set a “neutral” rating and a $8.00 price target on the stock. Needham & Company LLC restated a “hold” rating on shares of Adamas Pharmaceuticals in a research report on Friday, November 8th. Finally, Northland Securities reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Adamas Pharmaceuticals in a research note on Friday, November 8th. Three research analysts have rated the stock with a sell rating, five have given a hold rating and five have given a buy rating to the stock. Adamas Pharmaceuticals has a consensus rating of “Hold” and an average target price of $16.73.

Shares of NASDAQ:ADMS opened at $6.51 on Monday. The company has a market capitalization of $181.36 million, a P/E ratio of -1.34 and a beta of 1.77. Adamas Pharmaceuticals has a 1-year low of $3.35 and a 1-year high of $12.57. The firm’s 50 day simple moving average is $4.85 and its two-hundred day simple moving average is $5.47. The company has a debt-to-equity ratio of 6.72, a current ratio of 6.35 and a quick ratio of 6.15.

Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its quarterly earnings data on Thursday, November 7th. The specialty pharmaceutical company reported ($0.99) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.90) by ($0.09). The firm had revenue of $13.93 million during the quarter, compared to analysts’ expectations of $14.36 million. Adamas Pharmaceuticals had a negative return on equity of 205.30% and a negative net margin of 215.09%. On average, sell-side analysts anticipate that Adamas Pharmaceuticals will post -3.92 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Stonepine Capital Management LLC lifted its stake in Adamas Pharmaceuticals by 44.6% in the 2nd quarter. Stonepine Capital Management LLC now owns 1,423,578 shares of the specialty pharmaceutical company’s stock worth $8,826,000 after purchasing an additional 439,249 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of Adamas Pharmaceuticals by 5.4% during the 2nd quarter. BlackRock Inc. now owns 2,195,088 shares of the specialty pharmaceutical company’s stock valued at $13,609,000 after purchasing an additional 112,278 shares during the last quarter. Emerald Advisers LLC grew its position in shares of Adamas Pharmaceuticals by 11.8% during the second quarter. Emerald Advisers LLC now owns 700,176 shares of the specialty pharmaceutical company’s stock valued at $4,341,000 after purchasing an additional 73,929 shares in the last quarter. Emerald Mutual Fund Advisers Trust grew its position in shares of Adamas Pharmaceuticals by 9.1% during the second quarter. Emerald Mutual Fund Advisers Trust now owns 616,664 shares of the specialty pharmaceutical company’s stock valued at $3,823,000 after purchasing an additional 51,345 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Adamas Pharmaceuticals by 366.8% during the second quarter. Price T Rowe Associates Inc. MD now owns 58,797 shares of the specialty pharmaceutical company’s stock valued at $365,000 after purchasing an additional 46,200 shares in the last quarter. 51.99% of the stock is owned by institutional investors.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

Further Reading: Why do company’s buyback their stock?

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.